AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 252 min read$ONC

Wu Xiaobin sold $357K of ONC

Wu Xiaobin (President and COO) sold 1,292 shares of BeOne Medicines Ltd. (ONC) at $276.26 ($0.36M total) on 2026-06-23.

Original reporting
SEC EDGAR · Wu Xiaobin
Published Jun 25, 2026, 9:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 25, 2026, 9:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ONC
Neutral
medium confidence
Mentioned
$ONC
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ONCNeutralLow
01

Why it matters

This provides a fresh, primary-source datapoint on insider behavior (sale size, price, and post-sale holdings), but it does not include any new operational or clinical/regulatory catalyst.

02

Market read

Traders may monitor for follow-on insider activity, but the disclosure alone is unlikely to drive a sustained repricing without additional company-specific news.

03

What to watch

Insider sales often reflect diversification, tax planning, or scheduled liquidity needs; the filing shows holdings after transaction are 0 shares, but provides no stated rationale.

Relevance 4/10Novelty 5/10Timing: Filed 2026-06-25 after-hours; reflects sale executed 2026-06-23.

Background

The article is an SEC Form 4 insider transaction disclosure for BeOne Medicines Ltd. (ONC).

Company-level read

Ticker impact

$ONCNeutralMedium confidence
Context

SEC Form 4 shows Wu Xiaobin (President & COO) sold 1,292 ONC shares for about $356,927 on 2026-06-23.

Expected impact

Low near-term impact; any reaction is likely muted unless follow-on sales or other disclosures emerge.

Evidence & confidence

The filing is a Form 4 insider transaction with a small absolute size and no 10b5-1 plan stated; however, insider sales are common and not inherently bearish without additional context.

Market effects

Sector

Minimal—single-company insider sale in a biotech/meds name does not materially change sector risk.

Regional

Minimal—no macro or cross-regional linkage in the filing details.

Global

Minimal—no deal, trial, or regulatory action affecting global markets is disclosed.

Counterpoint

What could challenge this read

The absence of a stated 10b5-1 plan could be interpreted as discretionary selling, which some traders may read as near-term caution.

Key entities

  • issuer
    BeOne Medicines Ltd.

    Subject of the Form 4 insider transaction; President & COO Wu Xiaobin sold shares.

  • insider
    Wu Xiaobin

    President and COO who executed an open-market sale of 1,292 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ONC insider trading history →

Related articles

SEP 1
$ONCHighAI 9/10

FDA Approval Marks A Turning Point For BeOne Medicines (ONC)

BeOne Medicines (ONC) announced FDA approval for TEVIMBRA in combination with ZIIHERA and chemotherapy for HER2-positive gastroesophageal adenocarcinoma. The approval is based on Phase 3 trial data showing a median survival of 26.4 months. The company reported Q2 2026 revenue of $1.7 billion, up 30% YoY, and raised full-year revenue guidance to $6.6B-$6.8B. However, a Phase 3 study for zanubrutinib-sonrotoclax combination did not meet its primary endpoint.

yahoo.com2 min
SEP 1
$ALCMedAI 8/10

Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

President Trump's administration signed drug-pricing agreements with nine mid-sized pharmaceutical companies, including Astellas Pharma, Teva, and UCB, to lower U.S. drug prices under the MFN proposal. Companies agreed to reduce prices and invest $19.6B in U.S. manufacturing, with some contributing APIs to a government reserve. The deals cover 89% of the branded drug market, expanding beyond initial Big Pharma focus.

tradingview.com3 min
SEP 1
$ALCLow

Trump Expands Drug Pricing Agreements With 9 Drugmakers— RFK Jr. Says President Called ‘Every Hour’ to En

President Trump announced drug pricing agreements with nine pharmaceutical companies, including Alcon (ALC), BeOne (ONC), BridgeBio (BBIO), and Teva (TEVA). The deals require discounts on outpatient drugs for Medicaid and $19.6B in U.S. manufacturing investments. This expands the total to 26 companies, covering 90% of the U.S. market. The White House estimates $529B in savings over a decade.

benzinga.com2 min
AUG 31
$ONCHighAI 8/10

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer

BeOne Medicines reported positive Phase 3 trial results for ZIIHERA (zanidatamab) plus chemotherapy, with and without TEVIMBRA (tislelizumab), in HER2+ gastroesophageal cancer. The study met its primary endpoint, showing statistically significant overall survival benefits. The FDA recently approved these regimens for first-line treatment. BeOne has rights to ZIIHERA in Asia, Australia, and New Zealand.

leaderpost.com2 min